Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Terameprocol - Erimos Pharmaceuticals

Next Previous
X
Search
Drug Profile

Terameprocol - Erimos Pharmaceuticals

Alternative Names: CINelim; EM-1421; M4N; NSC 136955; Tetra-O-methyl nordihydroguaiaretic acid; Tetra-O-methyl-NDGA; Tetramethoxynordihydroguaiaretic acid; TMNDGA

Latest Information Update: 28 Oct 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Johns Hopkins University
  • Developer Erimos Pharmaceuticals; Johns Hopkins University; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  • Class Antineoplastics; Lignans; Small molecules
  • Mechanism of Action Apoptosis stimulants; BIRC5 protein inhibitors; Cdc2 kinase inhibitors; Mitosis inhibitors; Transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Glioblastoma
  • No development reported Alzheimer's disease; Bacterial infections; Cervical intraepithelial neoplasia; Diabetes mellitus; Haematological malignancies; Head and neck cancer; Herpes simplex virus infections; HIV infections; Human papillomavirus infections; Influenza virus infections; Leukaemia; Obesity; Psoriasis; Solid tumours

Most Recent Events

  • 28 Oct 2023 No recent reports of development identified for phase-I development in Glioblastoma(Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater) in USA (PO)
  • 04 Oct 2023 Erimos Pharmaceuticals completes a phase I trial for Glioblastoma (Recurrent, Metastatic disease, Late stage disease, Second-line therapy or greater) in USA (PO) (NCT02575794)
  • 03 May 2018 Phase-I/II development for Glioblastoma is ongoing in USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top